Favorable clinical response and drug retention of anti-IL-6 receptor inhibitor in rheumatoid arthritis with high CRP levels: the ANSWER cohort study.

Y. Nakayama,Motomu Hashimoto,Ryu Watanabe,Kosaku Murakami,Koichi Murata,Masao Tanaka,Hiromu Ito,Wataru Yamamoto,Kosuke Ebina,Kenichiro Hata,Hiramatsu Y,Masaki Katayama,Yonsu Son,Hideki Amuro,K. Akashi,Akira Onishi,Ryota Hara,Keiichi Yamamoto,Koichiro Ohmura,Shuichi Matsuda,A Morinobu

Favorable clinical response and drug retention of anti-IL-6 receptor inhibitor in rheumatoid arthritis with high CRP levels: the ANSWER cohort study.

2021

Currently, biological disease-modifying anti-rheumatic drugs (bDMARDs) with different modes of action [tumour necrosis factor inhibitor (TNFi), interleukin-6 receptor inhibitor (IL-6Ri), or cytotox...

Keywords:

Necrosis
Rheumatoid arthritis
Anti-IL-6
Pharmacology
Drug
Medicine
Cohort study
Receptor

Correction
Source
Cite
Save
Machine Reading By IdeaReader

References

Citations